ATF4 and cancer: In a therapeutic context, we further provide evidence that targeting the phosphorylation of eIF2 to induce cell death in leukemic cells may be a viable strategy for future therapies, as some potential anti-cancer drugs act via the eIF2/ATF4 signaling pathway, which in turn promotes apoptosis [52–59].